dalteparin has been researched along with Cerebral Infarction in 18 studies
Dalteparin: A low-molecular-weight fragment of heparin, prepared by nitrous acid depolymerization of porcine mucosal heparin. The mean molecular weight is 4000-6000 daltons. It is used therapeutically as an antithrombotic agent. (From Merck Index, 11th ed)
Cerebral Infarction: The formation of an area of NECROSIS in the CEREBRUM caused by an insufficiency of arterial or venous blood flow. Infarcts of the cerebrum are generally classified by hemisphere (i.e., left vs. right), lobe (e.g., frontal lobe infarction), arterial distribution (e.g., INFARCTION, ANTERIOR CEREBRAL ARTERY), and etiology (e.g., embolic infarction).
| Excerpt | Relevance | Reference |
|---|---|---|
| "The analyses used data from the Tinzapararin in Acute Ischaemic Stroke Trial, a randomized controlled trial assessing tinzaparin (low molecular weight heparin) versus aspirin in 1484 patients with acute ischemic stroke." | 5.14 | Asymptomatic hemorrhagic transformation of infarction and its relationship with functional outcome and stroke subtype: assessment from the Tinzaparin in Acute Ischaemic Stroke Trial. ( Bath, PM; Christensen, H; De Deyn, P; England, TJ; Geeganage, C; Leys, D; Moulin, T; O'Neill, D; Ringelstein, EB; Sare, GM; Woimant, F, 2010) |
| " We report a 22 year-old male with ulcerative colitis in treatment with mesalazine and prednisone presenting with headache and speech disturbances." | 3.81 | [Intracranial sinus venous thrombosis in ulcerative colitis. Report of one case]. ( Bagattini, JC; Calcagno, GP; Chiarella, M; Cohen, H; Forster, TA, 2015) |
| "After undergoing surgery for a ruptured aneurysm, 170 patients were randomized in a prospective, double-blind, placebo-controlled trial to test the effect of enoxaparin on the occurrence of ischemic lesions, which were demonstrated on follow-up CT scans available for 156 patients." | 2.71 | Risk factors for ischemic lesions following aneurysmal subarachnoid hemorrhage. ( Juvela, S; Porras, M; Poussa, K; Siironen, J; Varis, J, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (5.56) | 18.2507 |
| 2000's | 8 (44.44) | 29.6817 |
| 2010's | 4 (22.22) | 24.3611 |
| 2020's | 5 (27.78) | 2.80 |
| Authors | Studies |
|---|---|
| Brüggemann, R | 1 |
| Gietema, H | 1 |
| Jallah, B | 1 |
| Ten Cate, H | 1 |
| Stehouwer, C | 1 |
| Spaetgens, B | 1 |
| Kay, R | 1 |
| Wong, KS | 1 |
| Yu, YL | 1 |
| Chan, YW | 1 |
| Tsoi, TH | 1 |
| Ahuja, AT | 1 |
| Chan, FL | 1 |
| Fong, KY | 1 |
| Law, CB | 1 |
| Wong, A | 1 |
| Hui, CK | 1 |
| Yuen, MF | 1 |
| Ng, IO | 1 |
| Tsang, KW | 1 |
| Fong, GC | 1 |
| Lai, CL | 1 |
| Yasutaka, Y | 1 |
| Fujioka, S | 1 |
| Tsuboi, Y | 1 |
| Oyabu, K | 1 |
| Shibaguchi, H | 1 |
| Kamimura, H | 1 |
| Alay, H | 1 |
| Can, FK | 1 |
| Gözgeç, E | 1 |
| Gao, M | 1 |
| Lei, J | 1 |
| Patel, S | 1 |
| Sanborn, D | 1 |
| Issa, M | 1 |
| Calcagno, GP | 1 |
| Bagattini, JC | 1 |
| Forster, TA | 1 |
| Chiarella, M | 1 |
| Cohen, H | 1 |
| Fraint, E | 1 |
| Miller, R | 1 |
| Walter, A | 1 |
| Listernick, R | 1 |
| Wurm, G | 1 |
| Tomancok, B | 1 |
| Nussbaumer, K | 1 |
| Adelwöhrer, C | 1 |
| Holl, K | 1 |
| Vilkki, JS | 1 |
| Juvela, S | 2 |
| Siironen, J | 2 |
| Ilvonen, T | 1 |
| Varis, J | 2 |
| Porras, M | 2 |
| Poussa, K | 1 |
| Quartermain, D | 2 |
| Li, Y | 1 |
| Jonas, S | 2 |
| Diener, HC | 1 |
| England, TJ | 1 |
| Bath, PM | 2 |
| Sare, GM | 1 |
| Geeganage, C | 1 |
| Moulin, T | 1 |
| O'Neill, D | 2 |
| Woimant, F | 1 |
| Christensen, H | 1 |
| De Deyn, P | 1 |
| Leys, D | 2 |
| Ringelstein, EB | 1 |
| Gray, LJ | 1 |
| Sprigg, N | 1 |
| Sørensen, P | 1 |
| Lindenstrøm, E | 1 |
| Boysen, G | 1 |
| De Deyn, PP | 1 |
| Friis, P | 1 |
| Marttila, R | 1 |
| Olsson, JE | 1 |
| Ringelstein, B | 1 |
| van der Sande, JJ | 1 |
| Turpie, AG | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Improving Outcome in Subarachnoid Hemorrhage wIth Nadroparine[NCT04507178] | Phase 2 | 100 participants (Anticipated) | Interventional | 2022-02-02 | Recruiting | ||
| Pilot Study of Treatment With Intravenous Enoxaparin and/or Oral Minocycline to Limit Infarct Size After Ischemic Stroke[NCT00836355] | 6 participants (Actual) | Interventional | 2009-04-30 | Terminated (stopped due to Too few acute stroke patients available to meet enrollment requirements.) | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for dalteparin and Cerebral Infarction
| Article | Year |
|---|---|
Low molecular weight heparin and the treatment of ischemic stroke. Animal results, the reasons for failure in human stroke trials, mechanisms of action, and the possibilities for future use in stroke.
Topics: Animals; Anticoagulants; Calcium; Calcium Channel Blockers; Cerebral Infarction; Clinical Trials as | 2001 |
6 trials available for dalteparin and Cerebral Infarction
| Article | Year |
|---|---|
Low-molecular-weight heparin for the treatment of acute ischemic stroke.
Topics: Activities of Daily Living; Acute Disease; Aged; Brain Ischemia; Cerebral Hemorrhage; Cerebral Infar | 1995 |
Reduction of ischemic sequelae following spontaneous subarachnoid hemorrhage: a double-blind, randomized comparison of enoxaparin versus placebo.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Brain Ischemia; Cerebral Infarction; Double-Blind Me | 2004 |
Relationship of local infarctions to cognitive and psychosocial impairments after aneurysmal subarachnoid hemorrhage.
Topics: Cerebral Infarction; Double-Blind Method; Enoxaparin; Female; Humans; Male; Middle Aged; Neuropsycho | 2004 |
Risk factors for ischemic lesions following aneurysmal subarachnoid hemorrhage.
Topics: Adult; Aged; Aneurysm, Ruptured; Anticoagulants; Cerebral Infarction; Double-Blind Method; Enoxapari | 2005 |
Asymptomatic hemorrhagic transformation of infarction and its relationship with functional outcome and stroke subtype: assessment from the Tinzaparin in Acute Ischaemic Stroke Trial.
Topics: Aged; Anticoagulants; Aspirin; Cerebral Hemorrhage; Cerebral Infarction; Dose-Response Relationship, | 2010 |
Significant variation in mortality and functional outcome after acute ischaemic stroke between Western countries: data from the tinzaparin in acute ischaemic stroke trial (TAIST).
Topics: Activities of Daily Living; Adult; Aged; Aged, 80 and over; Cause of Death; Cerebral Infarction; Cro | 2006 |
11 other studies available for dalteparin and Cerebral Infarction
| Article | Year |
|---|---|
Arterial and venous thromboembolic disease in a patient with COVID-19: A case report.
Topics: Anticoagulants; Cerebral Infarction; Clopidogrel; Computed Tomography Angiography; Coronavirus Infec | 2020 |
Low molecular weight heparin-induced liver toxicity.
Topics: Adult; Anticoagulants; Cerebral Infarction; Chemical and Drug Induced Liver Injury; Complement C3; E | 2001 |
Liver toxicity of intravenous heparin treatment in patients with acute ischemic stroke.
Topics: Anticoagulants; Cerebral Infarction; Edaravone; Enoxaparin; Heparin; Humans; Ischemic Stroke; Liver; | 2023 |
Cerebral Infarction in an Elderly Patient with Coronavirus Disease.
Topics: Aged, 80 and over; Anticoagulants; Aspirin; Betacoronavirus; Cerebral Infarction; Coronavirus; Coron | 2020 |
Image and clinical analysis of common carotid web: a case report.
Topics: Aged; Anticoagulants; Aspirin; Basal Ganglia Diseases; Carotid Artery Diseases; Carotid Artery, Comm | 2021 |
57-Year-Old Woman With Weakness and Word-Finding Difficulties.
Topics: Adenocarcinoma, Clear Cell; Antibodies, Antiphospholipid; Aspirin; Biomarkers, Tumor; Cerebral Infar | 2021 |
[Intracranial sinus venous thrombosis in ulcerative colitis. Report of one case].
Topics: Anti-Inflammatory Agents; Anticoagulants; Cerebral Infarction; Colitis, Ulcerative; Enoxaparin; Head | 2015 |
Posterior Reversible Encephalopathy Syndrome and Cerebral Sinus Thrombosis in a Case of Pediatric B-Cell ALL.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Ischemia; Cerebral Infarction; Child, Preschoo | 2017 |
A 15-year-old girl with hypertension.
Topics: Adolescent; Anticoagulants; Antiphospholipid Syndrome; Cerebral Infarction; Enoxaparin; Female; Huma | 2011 |
Enoxaparin, a low molecular weight heparin decreases infarct size and improves sensorimotor function in a rat model of focal cerebral ischemia.
Topics: Animals; Brain Ischemia; Cerebral Infarction; Enoxaparin; Injections, Subcutaneous; Male; Motor Acti | 2000 |
[Initial results of the PROTECT Study publicized. Stroke patients need effective thrombosis prevention].
Topics: Anticoagulants; Cerebral Infarction; Double-Blind Method; Hemorrhage; Heparin; Heparin, Low-Molecula | 2005 |